Amoxycillin-clavulanate versus methicillin or isoxazolyl penicillins for treatment of Staphylococcus aureus infections.
Moreillon
P
P
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
D000658:Amoxicillin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins; D002352:Carrier Proteins / Q000378:metabolism; D002969:Clavulanic Acids / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006602:Hexosyltransferases; D008712:Methicillin / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D002267:Muramoylpentapeptide Carboxypeptidase / Q000378:metabolism; D010068:Oxacillin / Q000627:therapeutic use; D046915:Penicillin-Binding Proteins; D010405:Penicillinase / Q000378:metabolism; D010458:Peptidyl Transferases; D013203:Staphylococcal Infections / Q000188:drug therapy*; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002352:Carrier Proteins; D002969:Clavulanic Acids; D046915:Penicillin-Binding Proteins; D065093:beta-Lactamase Inhibitors; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase; D010405:Penicillinase; D008712:Methicillin; D010068:Oxacillin